Somewhere in your portfolio, you probably already own a big healthcare position you never chose.
An S&P 500 fund holds drugmakers, insurers and device companies. Many investors then add a pharma ETF on top and double the same bet.
That overlap is the most common slip we see with the best US healthcare and pharma ETFs.
The second is buying a narrow fund when the plan needed a broad one. Both feel sensible in the moment.
This guide works through five myths that steer long-term investors wrong. Each comes with what the fund documents actually say.
We then show how NRIs and resident Indians can buy these funds, and what tax looks like.
Two investors, one sector
Harpreet is a university lecturer in Manchester, originally from Ludhiana.
She has two young children and an illustrative GBP 640 monthly SIP into global equity. She also repays an NRI home loan on a flat in Mohali.
She wants a healthcare sleeve for the next twenty years. Her reasoning is simple: people age, and medicine keeps getting more advanced. Her UK platform mainly offers Ireland-domiciled funds.
The second investor is a Mumbai-based HNI. He recently sold an inherited flat and has an illustrative INR 1.15 crore to place.
His parents' medical costs are rising, and he wants some of that cost growth working for him.
Myth 1: Healthcare and pharma ETFs are the same thing
They are not. A broad healthcare ETF holds the whole sector. A pharma ETF holds only drugmakers.
The Health Care Select Sector SPDR ETF (XLV) tracks the healthcare sector of the S&P 500. State Street's fund page shows pharmaceuticals as the largest slice. Biotech, providers and services, medical equipment and life sciences tools make up the rest.
The iShares U.S. Pharmaceuticals ETF (IHE) is far narrower. BlackRock describes it as exposure to US drug manufacturers and vaccine producers.
Almost the entire fund sits in pharmaceuticals.
The difference matters over decades. Drug patents expire, and pricing pressure hits drugmakers first. Insurers, hospitals and device makers respond to different forces, so a broad fund smooths the ride.
Myth 2: A broad healthcare ETF is automatically diversified
Broad does not mean evenly spread. Sector funds weight companies by size. A handful of giants can dominate.
State Street's holdings list for XLV shows one drugmaker carrying a very large share of the fund. The top ten names make up a big portion of the total. That is concentration risk inside a "diversified" product.
Indexes respond in different ways. XLV's index caps single names.
Vanguard's Health Care ETF (VHT) covers a wider set of mid and small companies. It is the same breadth logic we apply when comparing VOO with VTI.
Check first: open the fund's holdings page before you buy. If one company exceeds a tenth of the fund, you are partly buying that company.
Myth 3: Biotech is where the long-term growth is
Biotech has produced some of the market's biggest winners.
It has also produced long, painful drawdowns. Many small biotechs have no profits yet and depend on a single drug trial.
The SPDR S&P Biotech ETF (XBI) uses a modified equal-weight index. State Street says it gives exposure across large, mid and small-cap biotech names. That means small, unproven companies count almost as much as giants.
State Street also positions XBI for targeted strategic or tactical positions, not broad sector investing. That is a useful signal from the issuer itself. For a twenty-year core holding, biotech works better as a small satellite.
The same caution applies to new listings. A GIFT City IPO or a US biotech debut is a bet on one story. Access through IPO platforms does not change that risk.
Myth 4: Healthcare is defensive, so it cannot fall much
Healthcare is often called defensive. People need medicine in recessions. Company earnings tend to hold up better than in cyclical sectors.
It still falls.
US drug pricing policy is a recurring source of pressure. Policy headlines can hit the whole group in a day. Patent cliffs, when a big drug loses protection, can drag a single heavyweight down for years.
There is also valuation risk. When investors crowd into a few obesity or oncology winners, their price-to-earnings ratios stretch. Defensive businesses can still be expensive stocks.
Short-term signals do not fix this. Watching the GIFT Nifty tracker or a weekly read on GIFT Nifty helps traders. It does not change a twenty-year healthcare thesis.
Myth 5: Indian pharma funds give the same exposure
They give a very different exposure. The NSE's Nifty Pharma factsheet shows an index of Indian drugmakers. Many of them earn a large part of their revenue from generic medicines.
US healthcare ETFs hold patent-owning innovators, insurers, hospital groups and device makers. Indian generics companies compete on manufacturing cost. Both can do well, but for different reasons.
A resident Indian holding Nifty Pharma already has drug-sector risk. Adding a US pharma ETF may stack the same policy risk twice. A broad US healthcare fund overlaps less.
Watch for: fund overlap across your whole portfolio. Our guide to mutual fund portfolio overlap shows how to check it.
The shortlist, by job
Here is how we would sort the main options. Each fund does a different job.
Core, US-listed: XLV for large-cap healthcare, or VHT for broader coverage including smaller companies.
Core, UCITS: the iShares S&P 500 Health Care Sector UCITS ETF, domiciled in Ireland. It has an accumulating USD share class.
Global core, UCITS: the Xtrackers MSCI World Health Care UCITS ETF, which adds European and Japanese drugmakers.
Satellite, pharma only: IHE, for investors who want drugmakers specifically.
Satellite, biotech: XBI, kept small.
Accumulating funds reinvest dividends instead of paying them out. Our UCITS ETFs guide and the explainer on why ETF domicile matters cover the trade-offs. For cost comparisons, look at expense ratio and tracking error together.
Domicile also affects estate exposure. The IRS states that some non-residents holding US assets must file a US estate tax return. Ireland-domiciled funds are one way many non-US investors reduce that exposure.
How to buy from India or abroad
Resident Indians buy overseas ETFs under the Liberalised Remittance Scheme. The RBI's LRS FAQs set out the permitted purposes and annual limit. Our overview of US investing from India walks through broker routes.
GIFT City offers a second route. Belong operates under IFSCA licences in GIFT City, and IFSC funds invest in dollars. You can browse the GIFT City fund screener by mandate.
Use the screener to check how much healthcare a global fund already holds. The DSP Global Equity Fund is one example with a global mandate. If it already carries healthcare names, a sector ETF on top may be overkill.
Other GIFT City funds carry different exposures. The Edelweiss Greater China Equity Fund is regional. The Tata India Dynamic Equity Fund and Sundaram's India mid-cap feeder hold Indian companies, which includes some Indian pharma.
NRIs on US-listed funds should file a W-8BEN form with their broker. It records non-US status for withholding. IRS Publication 515 explains how US withholding applies to non-resident aliens.
What each investor did
Harpreet split her plan into two layers. Most of her new SIP went into the S&P 500 Health Care UCITS ETF. A small slice went to the global healthcare UCITS fund for Europe and Japan.
She kept her dollar emergency buffer in a USD fixed deposit through Belong. A market fall would not force a sale.
She compared it first using our NRI FD rates tool. Our note on GIFT City FDs versus FCNR and NRE deposits helped her choose the account type.
The Mumbai investor put only part of the inheritance into healthcare. He staggered entry over a year, following the logic in our guide to SIP vs lump sum for US ETFs. He chose XLV as the core and capped XBI at a small fraction.
He also considered private healthcare strategies. The GIFT City AIF screener shows what is available, though minimums are high. Indian equity stayed in his mutual fund portfolio.
Part of the sale proceeds cleared a car loan, which keeps his credit profile clean for later. His parents' hospital bills go on one of the better Indian credit cards for rewards, paid in full each month.
Choosing between them
Sector funds sit on top of a core, not in place of one.
The choice comes down to what you already own and how long you will hold. Say your portfolio is mostly a broad S&P 500 or world fund. A healthcare ETF is then a deliberate overweight, and a modest one usually does the job.
For the whole sector over twenty years, a broad fund such as XLV, VHT or a UCITS equivalent fits. A pharma-only fund suits someone who believes specifically in drugmakers and accepts pricing risk. Biotech belongs only in a small slice you can watch fall by half without selling.
Doing nothing has a cost too. Without a plan, overlap builds quietly, and one stock can end up driving your results. Our piece on sector funds versus broad market funds covers this balance.
A planning timeline for a long-term holding
The rebalancing step is where most plans fail. Investors happily trim losers and let winners run unchecked. Our note on diversification versus concentration explains why the opposite habit protects you.
Signals that do not belong in this plan
Some tools are useful for traders and irrelevant for a twenty-year holding. GIFT Nifty futures and broader F&O trading are short-term instruments. They do not hedge sector risk in a US ETF.
The same goes for GIFT Nifty's past data and reading a GIFT Nifty chart. They describe Indian market mood overnight. Your healthcare ETF needs patience, not overnight cues.
Some investors also ask whether to pick drug stocks directly. A list of individual stocks to research is a fair starting point. For most people, though, a fund removes the single-trial and single-patent risk.
This is the part I find investors underestimate most. Time in the market matters more than clever timing, as our guide to timing versus time in the market shows.
Tax: go slowly here
Tax rules change, so treat this as a map, not a rate card. Confirm current treatment before you act.
For resident Indians, gains on foreign ETFs are taxed in India, and the holding must be reported in Schedule FA. See how US stocks and ETFs are taxed in India and our US stocks and ETFs guide. Dividend withholding in the US can be credited in India under the DTAA, subject to the rules.
NRIs pay tax where they are resident, and US withholding still applies to US-listed dividends. Returning NRIs face a shift once residency changes. Our guide on selling US stocks before returning to India covers the timing question.
Belong's tax filing service can help NRIs and returning residents report foreign ETFs correctly.
FAQs
Which is the best US healthcare ETF for long-term investing?
For most long-term investors, a broad fund such as XLV, VHT or a UCITS S&P 500 healthcare ETF fits best. They cover the whole sector. Pharma-only and biotech funds work better as smaller satellites.
Is a pharma ETF riskier than a healthcare ETF?
Usually, yes. A pharma ETF concentrates on drugmakers, so pricing policy and patent expiries hit the whole fund. A broad healthcare ETF spreads that risk across insurers, devices and services.
Can resident Indians buy US healthcare ETFs?
Yes, through an overseas broker under the RBI's Liberalised Remittance Scheme. GIFT City global funds offer another dollar-denominated route. Report the holdings in Schedule FA of your Indian return.
How much of my portfolio should go into healthcare ETFs?
There is no single right number. Most investors already hold healthcare through broad index funds. A sector ETF should be a modest, deliberate addition, sized after checking overlap.
What if I move back to India while holding these ETFs?
Your tax status changes as you shift from NRI to RNOR and then resident. Review the holding and its domicile before the move, ideally with an adviser.
Sources
State Street Global Advisors, Health Care Select Sector SPDR ETF (XLV)
State Street Global Advisors, SPDR S&P Biotech ETF (XBI)
BlackRock iShares, iShares U.S. Pharmaceuticals ETF (IHE)
BlackRock iShares, iShares S&P 500 Health Care Sector UCITS ETF
NSE Indices, Nifty Pharma index factsheet
Reserve Bank of India, FAQs on the Liberalised Remittance Scheme
IRS, Publication 515: Withholding of Tax on Nonresident Aliens
IRS, Some nonresidents with US assets must file estate tax returns
Disclaimer
This article is for general information and education only. It is not investment, tax or legal advice. Investments carry risk, including loss of capital, and past performance does not guarantee future results. Rates, rules and limits change, so verify current details with official sources and consult a qualified adviser before acting.
